Published by Frank Prenesti on 17th February 2021
(Sharecast News) - AstraZeneca said the phase 3 trial for breast cancer drug Lynparza would move to early primary analysis and reporting following a recommendation from the Independent Data Monitoring Committee (IDMC).
URL: http://www.digitallook.com/dl/news/story/31650320/...